CORONAVIRUS This medicine significantly reduces the risk of hospitalization and death! It also deals with OMIKRON – Topky

Laboratory tests lead to such conclusions. These have shown that sotrovimab, also known as Xevudy, reduces the risk of hospitalization and death in patients with a mild to moderate course by up to 89 percent. It is also suitable for immunocompromised people, but is no longer given to patients connected to oxygen.

Sotrovimab is a monoclonal antibody that is given by infusion. It works by binding to the SARS-CoV-2 virus spike protein, reducing its ability to penetrate cells in the human body. Studies have also shown that it is able to act on the new omicron variant.

Source: SITA / archive

In the USA, the drug can be used conditionally as early as May this year. Last week, sotrovimab was also approved by the UK Drug Administration for the treatment of patients at risk of developing severe COVID-19 symptoms. The European Medicines Agency announced in mid-November that it had begun examining its application for marketing authorization for Xevuda. They assumed that they could issue an opinion within two months.